Regen BioPharma Inc (RGBP) stock
Close on Oct 19, 2026Market cap $92.33KP/E –Yield –
Regen BioPharma Inc grew revenue 0.0% to $236.56K over the twelve months to Jun 30, 2026. At the latest close the market valued the company at $92.33K.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $92.33K
- P/E ratio
- –
- Price to sales
- 0.39
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Revenue
- $236.56K
- Net income
- -$1.19M
- EPS, diluted
- -$0.05
- Book value per share
- -$0.01
- Diluted shares
- 616M
Trading
- Previous close
- $0.00
- Open
- $0.00
- Day's range
- $0.00 – $0.00
- Volume
- 537,125
- Average volume (20 days)
- 3,815,881
Market cap history
Month-end market cap since 2014, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Oct 19, 2026. The S&P 500 is measured by the SPY fund.
| Period | RGBP | S&P 500 | Difference | RGBP per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | +50.0% | +0.6% | +49.4 pts | ||
| 3 months | +50.0% | +3.4% | +46.6 pts | ||
| Year to date | -98.0% | +13.3% | −111.3 pts | ||
| 1 year | -98.8% | +16.6% | −115.5 pts | ||
| 3 years | -100.0% | +86.4% | −186.4 pts | -94.4% | +23.1% |
| 5 years | -100.0% | +81.9% | −181.9 pts | -90.1% | +12.7% |
| 10 years | -100.0% | +318.9% | −418.9 pts | -73.5% | +15.4% |
Fourteen years at a glance
Fiscal years 2012 to 2025 and trailing twelve months, USD
Revenue
Operating income
Net income
EPS, diluted
Press releases
Releases Regen BioPharma filed with the SEC as exhibits to Form 8-K or 6-K
About Regen BioPharma
Pharmaceutical Preparations
Regen Biopharma, Inc. is a biotechnology company focused on developing regenerative medicine therapies. The company targets treatments across oncology and aplastic anemia, with therapeutic candidates including HemaXellerate, dCellVax, tCellVax, DiffronC, and DuraCar, alongside patented small molecules targeting NR2F6. Its programs incorporate cellular compositions, siRNA gene silencing, mRNA cancer vaccines, and CAR-T cell engineering. Regen Biopharma advances its pipeline through internal development and commercialization partnerships, including licensing arrangements that grant external entities rights to apply its technologies toward veterinary therapeutics and human pancreatic cancer treatments.
Company profile, executives and historyRegen BioPharma stock: common questions
What is Regen BioPharma's stock price?
RGBP closed at $0.00 on Oct 19, 2026, up 50.00% on the day.
What is Regen BioPharma's market cap?
Regen BioPharma was worth $92.33K at the close on Oct 19, 2026: the share price times the diluted shares outstanding.
What is RGBP's P/E ratio?
Regen BioPharma lost money over fiscal 2025 (diluted EPS -$0.05), so it has no meaningful P/E ratio.
How much revenue does Regen BioPharma make?
Regen BioPharma reported revenue of $236.56K for the twelve months to Jun 30, 2026, up 0.0% from a year earlier.
Does Regen BioPharma pay a dividend?
No. Regen BioPharma has not paid a cash dividend over the last twelve months.
How has RGBP stock performed over the past year?
Including dividends, RGBP returned -98.8% over the past year, against +16.6% for the S&P 500.
Who are Regen BioPharma's competitors?
Companies most similar to Regen BioPharma by business, industry and size include LIPO, ERNA, GDTC, RDHL, ABVC.
See a number that looks wrong?